Download PDF
Dtsch Med Wochenschr 2012; 137(10): 481-486
DOI: 10.1055/s-0031-1298905
Übersicht | Review article
Onkologie, Arbeitsmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Das maligne Mesotheliom der Pleura

Malignant pleural mesothelioma
T. Ploenes
1   Abt. Thoraxchirurgie der Albert-Ludwigs Universität Freiburg
,
T. Osei-Agyemang
1   Abt. Thoraxchirurgie der Albert-Ludwigs Universität Freiburg
,
U. Nestle
2   Klinik Strahlenheilkunde der Albert-Ludwigs Universität Freiburg
,
C. F. Waller
3   Abt. Innere Medizin I der Albert-Ludwigs Universität Freiburg
,
B. Passlick
1   Abt. Thoraxchirurgie der Albert-Ludwigs Universität Freiburg
› Author Affiliations
Further Information

Publication History

03 August 2011

10 November 2011

Publication Date:
28 February 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das maligne Mesotheliom der Pleura (MMP) ist ein hoch aggressiver Tumor, welcher dem pleuralen Mesothel entstammt. Die Asbestexposition ist der wichtigste Faktor in der Pathogenese des MMP und entsprechend des erst späten Verbots dieser Substanz im Jahre 2005 wird der Gipfel der Neuerkrankungen in Europa für die nächsten zwanzig Jahre erwartet. Das stark aggressive Verhalten dieses Tumors zeigt sich in einer schlechten Prognose mit einem mittleren Überleben zwischen sieben und neun Monaten. Trotz aller Fortschritte, die in der Diagnostik und Therapie dieser Entität gemacht wurden, ist die optimale Behandlung immer noch Gegenstand der Diskussion. In diesem Artikel wird der aktuelle Stand der Diagnostik und Therapie diskutiert.

Abstract

Malignant pleural mesothelioma (MMP) is a highly aggressive tumor arising of the pleural mesothelium. Asbestos exposure is the main factor involved in the pathogenesis of MMP and according to the late ban of this agent in 2005 the peak incidence in Europe is expected in the next twenty years. The highly aggressive behaviour of this tumor results in a poor prognosis with a mean overall survival between 7 and 9 months. Despite the progress made in diagnosis and therapy of this entity the optimal treatment remains a subject of debate. In this article we review the current state of treatment and diagnosis.

Schlüsselwörter

intracavitäre hypertherme Chemotherapie - Asbest - multimodale Therapie - Mesotheliom

Keywords

intracavitary intraoperative hyperthermic chemotherapy - asbestos - multimodal treatment - mesothelioma
 

  • Literatur

  • 1 Alberts AS, Falkson G, Goedhals L et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527-535
    PubMedGoogle Scholar
  • 2 Antony VB, Loddenkemper R, Astoul P et al. Management of malignant pleural effusions. Eur Respir J 2001; 18: 402-419
    CrossrefPubMedGoogle Scholar
  • 3 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Diagnostik und Begutachtung asbestbedingter Berufskrankheiten. http://www.awmf.org/uploads/tx_szleitlinien/002-038l_S2k-Diagnostik_und_Begutachtung_asbestbedingter_Berufskrankheiten_2010-12.pdf
    PubMedGoogle Scholar
  • 4 Balduyck B, Trousse D, Nakas A et al. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?. Ann Thorac Surg 2010; 89: 907-911
    CrossrefPubMedGoogle Scholar
  • 5 Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol) 1991; 3: 315-317
    CrossrefPubMedGoogle Scholar
  • 6 Bogliolo GV, Lerza R, Bottino GB et al. Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 1991; 27: 839-842
    PubMedGoogle Scholar
  • 7 Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-758
    CrossrefPubMedGoogle Scholar
  • 8 Branscheid D, Krysa S, Bauer E et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 1991; 5: 466-472
    CrossrefPubMedGoogle Scholar
  • 9 Cao CQ, Yan TD, Bannon PG et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010; 5: 1692-1703
    CrossrefPubMedGoogle Scholar
  • 10 Ceresoli GL, Locati LD, Ferreri AJ et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34: 279-287
    CrossrefPubMedGoogle Scholar
  • 11 Chi A, Liao Z, Nguyen NP et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1132-1141
    CrossrefPubMedGoogle Scholar
  • 12 British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001; 56: 250-265
    CrossrefPubMedGoogle Scholar
  • 13 Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994; 38: 212-214
    CrossrefPubMedGoogle Scholar
  • 14 de Bree E, van Ruth S, Baas P et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480-487
    CrossrefPubMedGoogle Scholar
  • 15 Deutschen Gesetzlichen Unfallversicherung DGUV. http://www.dguv.de/inhalt/zahlen/bk/bestaetigte/index.jsp abgerufen am 05.09.2011
    PubMed
  • 16 Elmes PC, Simpson JC. The clinical aspects of mesothelioma. Q J Med 1976; 45: 427-449
    PubMedGoogle Scholar
  • 17 Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620-626
    CrossrefPubMedGoogle Scholar
  • 18 Flores RM, Zakowski M, Venkatraman E et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007; 2: 957-965
    CrossrefPubMedGoogle Scholar
  • 19 Goldberg M, Imbernon E, Rolland P et al. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006; 63: 390-395
    CrossrefPubMedGoogle Scholar
  • 20 Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 1999; 56: 505-513
    CrossrefPubMedGoogle Scholar
  • 21 Husain AN, Colby TV, Ordonez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331
    PubMedGoogle Scholar
  • 22 Iwatsubo Y, Pairon JC, Boutin C et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study. Am J Epidemiol 1998; 148: 133-142
    CrossrefPubMedGoogle Scholar
  • 23 Kent M, Rice D, Flores R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2008; 9: 158-170
    CrossrefPubMedGoogle Scholar
  • 24 Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34: 718-721
    PubMedGoogle Scholar
  • 25 Lerza R, Esposito M, Vannozzi M et al. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses. Cancer 1994; 73: 79-84
    CrossrefPubMedGoogle Scholar
  • 26 Leslie H, Sobin MKG, Wittekind C Hrsg. TNM Classification of Malignant Tumours (UICC International Union Against Cancer). 7th. Edition. Aufl; 2009
    Google Scholar
  • 27 Low EM, Khoury GG, Matthews AW et al. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Clin Oncol (R Coll Radiol) 1995; 7: 317-318
    CrossrefPubMedGoogle Scholar
  • 28 Merritt N, Blewett CJ, Miller JD et al. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001; 78: 171-174
    CrossrefPubMedGoogle Scholar
  • 29 Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694
    CrossrefPubMedGoogle Scholar
  • 30 Neumann V, Gunthe S, Mulle KM et al. Malignant mesothelioma--German mesothelioma register 1987-1999. Int Arch Occup Environ Health 2001; 74: 383-395
    CrossrefPubMedGoogle Scholar
  • 31 Neumann V, Rutten A, Scharmach M et al. Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register. Int Arch Occup Environ Health 2004; 77: 191-199
    CrossrefPubMedGoogle Scholar
  • 32 O'Rourke N, Garcia JC, Paul J et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22
    CrossrefPubMedGoogle Scholar
  • 33 Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672
    CrossrefPubMedGoogle Scholar
  • 34 Pilling JE, Stewart DJ, Martin-Ucar AE et al. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2004; 25: 497-501
    CrossrefPubMedGoogle Scholar
  • 35 Ribak J, Lilis R, Suzuki Y et al. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death. Br J Ind Med 1988; 45: 182-187
    PubMedGoogle Scholar
  • 36 Richards WG, Zellos L, Bueno R et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24: 1561-1567
    CrossrefPubMedGoogle Scholar
  • 37 Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-1168
    PubMedGoogle Scholar
  • 38 Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788-795
    CrossrefPubMedGoogle Scholar
  • 39 Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495
    CrossrefPubMedGoogle Scholar
  • 40 Schipper PH, Nichols FC, Thomse KM et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008; 85: 257-264
    CrossrefPubMedGoogle Scholar
  • 41 Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63
    CrossrefPubMedGoogle Scholar
  • 42 Takagi K, Tsuchiya R, Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001; 31: 57-65
    CrossrefPubMedGoogle Scholar
  • 43 Tilleman TR, Richards WG, Zellos L et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138: 405-411
    CrossrefPubMedGoogle Scholar
  • 44 Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004; 45 (Suppl. 01) 103-119
    CrossrefPubMedGoogle Scholar
  • 45 van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889
    CrossrefPubMedGoogle Scholar
  • 46 Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644
    CrossrefPubMedGoogle Scholar
  • 47 Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-271
    PubMedGoogle Scholar
  • 48 Weder W, Opitz I, Stahel R. Multimodality strategies in malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009; 21: 172-176
    CrossrefPubMedGoogle Scholar
  • 49 Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008; 9: 147-157
    CrossrefPubMedGoogle Scholar